Comparative Pharmacology
Head-to-head clinical analysis: EMADINE versus OPCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMADINE versus OPCON A.
EMADINE vs OPCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Emedastine is a selective histamine H1 receptor antagonist that inhibits histamine-induced vascular permeability, edema, and pruritus.
Synthetic vasopressin analog; stimulates V1 receptors on vascular smooth muscle causing vasoconstriction, and V2 receptors in renal collecting ducts increasing water reabsorption.
1 drop of 0.05% ophthalmic solution in the affected eye(s) twice daily, approximately 8 hours apart.
0.1% ophthalmic solution: 1 drop in the affected eye(s) every 3-4 hours as needed for redness relief.
None Documented
None Documented
Terminal elimination half-life: 4–6 hours; clinically, dosing every 4–6 hours as needed for symptom relief
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in renal impairment.
Renal: approximately 60% as unchanged drug and metabolites; fecal: approximately 15%
Primarily renal excretion of unchanged drug and metabolites; about 70-80% of the dose eliminated via urine within 24 hours, with 10-20% fecal elimination.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine/Decongestant Combination